Context Therapeutics Inc. (NASDAQ:CNTX) Receives $6.80 Average Target Price from Brokerages

Shares of Context Therapeutics Inc. (NASDAQ:CNTX) have received a consensus recommendation of “Buy” from the seven ratings firms that are covering the stock, MarketBeat reports. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $6.33.

Several research firms have weighed in on CNTX. JMP Securities began coverage on shares of Context Therapeutics in a research report on Wednesday, January 8th. They issued an “outperform” rating and a $4.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $6.00 target price on shares of Context Therapeutics in a report on Monday, September 23rd. D. Boral Capital started coverage on Context Therapeutics in a research report on Monday, November 25th. They set a “buy” rating and a $9.00 target price on the stock. Finally, Citizens Jmp upgraded Context Therapeutics to a “strong-buy” rating in a research report on Wednesday, January 8th.

Context Therapeutics Stock Performance

CNTX stock opened at $1.08 on Wednesday. The company has a market cap of $81.00 million, a price-to-earnings ratio of -1.19 and a beta of 2.10. The business’s 50-day moving average is $1.47 and its two-hundred day moving average is $1.92. Context Therapeutics has a fifty-two week low of $0.89 and a fifty-two week high of $2.75.

Context Therapeutics (NASDAQ:CNTX) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.11). Equities analysts predict that Context Therapeutics will post -0.51 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Renaissance Technologies LLC boosted its stake in Context Therapeutics by 63.4% in the 2nd quarter. Renaissance Technologies LLC now owns 65,200 shares of the company’s stock worth $131,000 after purchasing an additional 25,300 shares during the period. Ally Bridge Group NY LLC lifted its holdings in shares of Context Therapeutics by 159.8% in the second quarter. Ally Bridge Group NY LLC now owns 1,886,232 shares of the company’s stock worth $3,782,000 after buying an additional 1,160,281 shares in the last quarter. Great Point Partners LLC bought a new position in shares of Context Therapeutics during the second quarter worth $14,876,000. Affinity Asset Advisors LLC grew its stake in Context Therapeutics by 392.4% during the second quarter. Affinity Asset Advisors LLC now owns 1,619,140 shares of the company’s stock valued at $3,246,000 after acquiring an additional 1,290,323 shares in the last quarter. Finally, Blue Owl Capital Holdings LP bought a new stake in Context Therapeutics in the 2nd quarter valued at $10,348,000. Institutional investors own 14.03% of the company’s stock.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.